Abstract #2406

Analysis of liver function after molecular targeting therapy of HCC with hepatocyte fraction index obtained from gadoxetic acid-enhanced MRI.

Yudai Syogan¹, Satoshi Kobayashi¹, Yu Ueda², Noboru Taniguchi¹, Naoki Ohno¹, Tosiaki Miyati¹, Toshifumi Gabata³, Takeshi Terashima⁴, Kuniaki Arai⁴, and Tatsuya Yamashita⁴

¹Quantum Medical Technology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ²Philips.Japan, Tokyo, Japan, ³Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁴Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

Hepatocyte fraction index (HeFra index) obtained from gadoxetic acid-enhanced MR imaging might be possible surrogate marker of liver function after molecular targeting therapy to advanced HCC, and the molecular targeting therapy to advanced HCC do not affect the function of background liver parenchyma.

This abstract and the presentation materials are available to members only; a login is required.

Join Here